IBAB Ion Beam Applications SA

IBA’s Proteus®ONE selected by Advocate Radiation Oncology for new proton therapy center in Florida

IBA’s Proteus®ONE selected by Advocate Radiation Oncology for new proton therapy center in Florida

Louvain-La-Neuve, Belgium, April 07, 2021 –  IBA(Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that its Proteus®ONE1 compact proton therapy solution has been selected by Advocate Radiation Oncology in conjunction with its affiliate Southwest Florida Proton for its  new radiation oncology center. The site will serve the greater population of Southwest Florida in a centralized location between Lee and Collier County.

The parties have signed a binding term sheet for the delivery of IBA’s Proteus®ONE solution including Pencil Beam Scanning (PBS), and a fully integrated quality assurance (QA) hardware and software package from IBA Dosimetry America, Inc. The term sheet includes long-term operation and maintenance services to be provided by IBA. Advocate Radiation Oncology expects to start treating patients by 2023. The typical end-user price for a Proteus®ONE system with a 10-year maintenance contract usually ranges between 40 and 50 million US dollars. Both parties will be working diligently to complete negotiations of the final agreement in the coming months. IBA will start recognizing revenue once the final agreement is executed.

Olivier Legrain, Chief Executive Officer of IBA, commented: “As we have highlighted previously, the US is of key strategic importance for our business overall and this latest agreement reinforces our leading position in this market, being our 17th proton therapy system there. The agreement also includes both proton therapy and dosimetry elements, demonstrating the strong synergies between these two business divisions. We look forward to supporting Advocate Radiation Oncology’s world-class practice in providing cancer patients with access to the most advanced radiotherapy technology.”

Dr. Arie Dosoretz, Managing Partner at Advocate Radiation Oncology, added: “At Advocate Radiation Oncology, our driving purpose and passion is to provide the most innovative radiation therapy available to the patients who need our help. Exploiting the capabilities of advanced proton therapy is the logical next step in our mission to lead the fight against cancer. We know that IBA’s experience and industry leading technology makes IBA’s Proteus®ONE the clear choice for this endeavor. We are excited to bring a beacon of hope to our community.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About Advocate Radiation Oncology

Advocate Radiation Oncology is a locally owned practice with convenient locations in South Florida. The practice’s mission is to provide compassionate health care expertise to cancer patients. Advocate Radiation Oncology is directed by a team of world-class, board-certified radiation oncologists,

For more information, please visit . 

CONTACTS

Soumya Chandramouli

Chief Financial Officer



Olivier Lechien

Corporate Communication Direcor



Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700






1 Proteus®ONE is the brand name of Proteus®235



Attachment



EN
07/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA Notice of Half Year 2025 Results and Conference Call

IBA Notice of Half Year 2025 Results and Conference Call HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST Louvain-la-Neuve, Belgium, 07 August 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The con...

 PRESS RELEASE

IBA : Publication des résultats du premier semestre 2025 et conférence...

IBA : Publication des résultats du premier semestre 2025 et conférence web La conférence sur les résultats des six premiers mois de 2025 aura lieu le jeudi 28 août 2025 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 7 août 2025 - IBA (Ion Beam Applications S.A le leader mondial des technologies d’accélération de particules, annonce qu’elle publiera ses résultats financiers consolidés du premier semestre le jeudi 28 août 2025 à 7h00, heure de Bruxelles. Informations relatives à la conférence La direction du Groupe IBA présentera les résultats des six premiers mois de l’année ...

 PRESS RELEASE

IBA – Transparency Notification - Denominator

IBA – Transparency Notification - Denominator                                                                                                                   June 30th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision:  « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as...

 PRESS RELEASE

IBA – Notification de Transparence - Dénominateur

IBA – Notification de Transparence - Dénominateur 30 juin 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »). En vertu de cette disposition : « [...] l'émetteur publie le total du capital, le nombre total de titres conférant le droit de vote et de droits de vote, ainsi que, par catégorie, le nombre de titres conférant le droit de vote et de ...

Guy Sips ... (+2)
  • Guy Sips
  • Michiel Declercq

ResearchPool Subscriptions

Get the most out of your insights

Get in touch